Kymera Therapeutics, Inc.
KYMR
$61.00
$1.111.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -50.05% | -49.51% | -25.85% | -40.11% | 86.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -50.05% | -49.51% | -25.85% | -40.11% | 86.92% |
| Cost of Revenue | 37.56% | 39.10% | 38.85% | 27.06% | 23.52% |
| Gross Profit | -94.88% | -104.18% | -83.04% | -74.84% | -1.09% |
| SG&A Expenses | 10.02% | 9.33% | 15.09% | 15.43% | 17.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.58% | 32.46% | 33.50% | 24.44% | 22.07% |
| Operating Income | -68.18% | -72.63% | -60.72% | -55.08% | -5.64% |
| Income Before Tax | -76.22% | -74.49% | -55.82% | -52.32% | -0.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -76.22% | -74.49% | -55.82% | -52.32% | -0.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.22% | -74.49% | -55.82% | -52.32% | -0.01% |
| EBIT | -68.18% | -72.63% | -60.72% | -55.08% | -5.64% |
| EBITDA | -69.80% | -72.70% | -60.43% | -54.45% | -4.20% |
| EPS Basic | -54.48% | -44.10% | -23.89% | -17.79% | 19.05% |
| Normalized Basic EPS | -57.29% | -48.38% | -27.43% | -15.03% | 21.47% |
| EPS Diluted | -54.48% | -44.10% | -23.89% | -17.79% | 19.05% |
| Normalized Diluted EPS | -57.29% | -48.38% | -27.43% | -15.03% | 21.47% |
| Average Basic Shares Outstanding | 17.74% | 21.45% | 25.72% | 28.48% | 19.61% |
| Average Diluted Shares Outstanding | 17.74% | 21.45% | 25.72% | 28.48% | 19.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |